Aveir VR LP: When to Convert to LBBAP

Question

When would you recommend to stop an Aveir VR LP and place a LBBAP pacemaker, with the Aveir VR having 20 months of functioning and functioning with the usual nocturnal no capture in single chamber LP and usual discomfort due to the atria ventricular asynchrony, with battery life expectancy of the device of 5 years and output voltage of 400 V @ 0.4ms?

Answer

Below is a practical, electrophysiology-oriented framework for deciding when to stop relying on an Aveir VR leadless pacemaker (LP) and convert to a left bundle branch area pacing (LBBAP) system, given the scenario you described.

Clinical context

• Device: Aveir VR (single-chamber leadless pacemaker)
• Time in service: ~20 months
• Issues:
  • Recurrent nocturnal non-capture (a known LP limitation in some patients)
  • Symptoms compatible with AV dyssynchrony / pacemaker syndrome (discomfort, reduced tolerance)
• Programming: ~4.0 V @ 0.4 ms (already relatively high output)
• Battery longevity: ~5 years remaining (not yet near elective replacement)

When conversion to LBBAP is recommended

I would strongly consider implanting an LBBAP pacemaker (and no longer relying on the Aveir VR as the primary pacing strategy) when one or more of the following are present, especially if they persist despite reasonable optimization:

1) Symptomatic AV dyssynchrony (pacemaker syndrome)

This is often the most compelling reason to convert.

• Typical symptoms: chest discomfort, dyspnea, fatigue, presyncope, reduced exercise tolerance.
• Rationale: a single-chamber ventricular LP cannot restore AV synchrony. LBBAP with a dual-chamber system can re-establish AV timing and improve hemodynamics.

2) Recurrent nocturnal non-capture despite adequate safety margin

• Night-predominant events (often related to higher vagal tone and/or threshold variability)
• Need for high output (e.g., ≥4.0 V @ 0.4 ms) to suppress events, or persistent events even at high output
• Symptoms or clinically meaningful pauses associated with the episodes

Rationale: further increasing output can reduce longevity and still may not fully eliminate non-capture if thresholds fluctuate. Switching pacing modality is frequently more effective than chasing thresholds.

3) Early battery inefficiency driven by high outputs

Needing high output only ~20 months into service suggests a higher likelihood of future reintervention. If the patient is symptomatic and you anticipate another procedure within a few years, it can be preferable to upgrade sooner rather than prolong a suboptimal strategy.

4) High expected lifetime pacing burden / pacing dependence

When long-term pacing is expected, physiologic pacing (like LBBAP) is generally favored to reduce the long-term risk of ventricular dyssynchrony and pacing-induced cardiomyopathy compared with conventional RV pacing strategies.

5) No overriding reason to remain leadless-only

If there is no active infection, venous access is acceptable, and procedural risk is reasonable, then the original advantage of a leadless-only approach can be outweighed by persistent symptoms and recurrent non-capture.

What to do with the existing Aveir VR

In most non-infection scenarios, the usual approach is to leave the leadless device in place and program it as:

• OOO (off), or
• VVI at a very low backup rate

Extraction is typically reserved for specific indications (e.g., infection, device interference, or other compelling reasons).

Bottom line

Given symptomatic AV dyssynchrony and recurrent nocturnal non-capture at relatively high output, it is reasonable to recommend conversion to an LBBAP pacemaker now rather than waiting for battery depletion, because this reflects a limitation of the pacing strategy (single-chamber ventricular leadless pacing) rather than something that can reliably be “programmed away.”

Medical note: This is general educational information and not a substitute for individualized clinical evaluation by the treating electrophysiology team.